Cytokinetics (CYTK) CEO logs 7,931-share tax-related stock sale

Rhea-AI Filing Summary

Cytokinetics President & CEO Robert I. Blum reported a small share sale primarily to cover tax obligations. On 2026-03-09, he sold 7,931 shares of common stock at $60.72 per share, described as a sell-to-cover transaction for company tax withholding on vested RSUs.

After this transaction, Blum directly holds 391,673 common shares, indicating the sale represents a minor portion of his direct stake. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.

Insider Trade Summary

Net Seller: 7,931 shares ($481,570)

Net Sell 3 txns

Insider Blum Robert I

Role President & CEO

Sold 7,931 shs ($482K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,931	$60.72	$482K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 391,673 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1)

Footnotes (1)

1. Sell to cover transaction to satisfy company tax withholding obligations upon vesting of RSUs. Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		7,931	D	$60.72	391,673	D
Common Stock								2,083	I	by Trust 1(2)
Common Stock								2,083	I	by Trust 2(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell to cover transaction to satisfy company tax withholding obligations upon vesting of RSUs.

2. Shares held by The Bridget Blum 2003 Irrevocable Trust.

3. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cytokinetics (CYTK) CEO Robert Blum report in this Form 4?

Robert I. Blum reported a small disposition of Cytokinetics common stock. He sold 7,931 shares on March 9, 2026, mainly to cover company tax withholding obligations arising from the vesting of restricted stock units, rather than as a discretionary open-market sale.

How many Cytokinetics (CYTK) shares did the CEO sell and at what price?

Robert Blum sold 7,931 shares of Cytokinetics common stock at $60.72 per share on March 9, 2026. The filing describes this as a sell-to-cover transaction intended to satisfy company tax withholding obligations tied to vesting RSUs.

How many Cytokinetics (CYTK) shares does the CEO hold after this transaction?

Following the reported sale, Robert Blum directly holds 391,673 Cytokinetics common shares. The filing also shows 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings associated with him.

Was the Cytokinetics (CYTK) CEO’s share sale a routine tax withholding event?

Yes. A footnote states the 7,931-share sale was a “sell to cover” transaction used to satisfy company tax withholding obligations upon vesting of RSUs. Such transactions typically reflect tax compliance mechanics rather than a discretionary decision to reduce ownership.

What indirect Cytokinetics (CYTK) holdings are reported for Robert Blum?

The Form 4 lists two indirect positions for Robert Blum. It reports 2,083 shares of Cytokinetics common stock held by The Bridget Blum 2003 Irrevocable Trust and another 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, both identified as indirect ownership interests.

Does this Cytokinetics (CYTK) Form 4 show any option exercises or derivatives?

No option exercises or derivative transactions are reported. The filing shows one non-derivative sale of 7,931 common shares for tax withholding purposes and two holding entries for indirect trust-owned shares, with no derivative positions listed in the derivative summary section.